28 Aug 2020 07:00
Yourgene Health plc
("Yourgene" or the "Company")
Notice of AGM & Annual Report 2020
Manchester, UK - 28 August 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Annual General Meeting ('AGM') will be held at 4:00pm on 22 September 2020.
As a result of the public safety measures introduced by the UK Government in response to the Covid-19 pandemic which were passed into law in England and Wales on 26 March 2020, and measures relating to the conduct of general meetings recently introduced by the Corporate Insolvency and Governance Act, the Board is adopting a number of changes to the traditional running of the AGM.
The AGM will be held virtually and run as a closed physical meeting. A very limited number of Company personnel will be present to conduct the meeting such that the minimum quorum requirements can be met. Shareholders will not be entitled to attend the meeting in person.
Shareholders wishing to vote on any of the matters of business are strongly advised to appoint the Chairman of the meeting as their proxy. If you attempt to appoint a named individual other than the Chairman of the meeting such individual will not be permitted to attend the meeting and instead you will be deemed to have appointed the Chairman of the meeting as your proxy. Shareholders may appoint a proxy through completion of a form of proxy, which can be submitted to the Company's Registrar online at www.signalshares.com. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice of Meeting. For your vote to be valid please ensure that it is received by no later than 4.00pm on Friday 18 September 2020.
The Company will provide a facility for shareholders to join the AGM either online or telephonically and the Company's CEO, Lyn Rees, will provide shareholders with a short presentation after the formal business of the AGM concludes, which will be made available on the Company website after the event. There will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that Shareholders register for the meeting and submit questions in advance, before 5:00pm (BST) on 20 September 2020.
To register for dial-in details and to submit any questions please contact Walbrook PR via email at yourgene@walbrookpr.com or call +44 (0)20 7933 8780.
The Notice of AGM and Form of Proxy will shortly be available on the Company's website at:
www.yourgene-health.com/investors/key-documents/shareholder-communications and are being posted to those shareholders who have opted out of electronic communications.
The Annual Report and Accounts for the year ended 31 March 2020, published on 28 July 2020, are available at:
www.yourgene-health.com/investors/key-documents/financial-reports
For more information, please contact:
| ||
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing
| Tel: +44 (0)161 669 8122 investors@yourgene-health.com
| |
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie / Ludovico Lazzaretti
| Tel: +44 (0)20 7213 0880 | |
N+1 Singer (Joint Corporate Broker) Aubrey Powell / Tom Salvesen / George Tzimas
Stifel Nicolaus Europe Limited (Joint Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison
| Tel: +44 (0)20 7496 3000
Tel: +44 (0)20 7710 7600 | |
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne
| Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Mob: 07980 541 893 / 07584 391 303
| |
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.